Literature DB >> 28671728

Clonality analysis of synchronous gastro-oesophageal junction carcinoma and distal gastric cancer by whole-exome sequencing.

Xiaofang Xing1, Shuqin Jia2, Jianmin Wu3, Qin Feng4, Bin Dong4, Bo Li5, Yongning Jia6, Fei Shan6, Ying'ai Li6, Yan Zhang6, Ying Hu7, Xiaodong Wang8, Xiangtao Liu8, Weishi Yu8, Lianhai Zhang6, Zhaode Bu6, Aiwen Wu6, Ziyu Li6, Jiafu Ji1,2,5,6.   

Abstract

Gastro-oesophageal junction (GEJ) carcinoma and distal gastric cancer (GC) have distinct epidemiology and clinical features and their relationship is uncertain. Synchronous multiple gastric cancers located mostly at proximal and distal sites provide rare specimens for investigating the comprehensive genomic relationships among these cancers in the context of identical genetic circumstances. Formalin-fixed, paraffin-embedded (FFPE) samples from 12 patients with synchronous GEJ carcinoma and distal GC were collected in this study. Whole-exome sequencing (WES) was performed using normal tissues as a control. Mutational profiling, clonality analysis, a detailed clinico-pathological review, determination of MSI status, EBER in situ hybridization (ISH), and programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1) immunohistochemical staining were performed. Twenty-three of the 24 samples were microsatellite-stable (MSS). Subclonal analysis revealed that nine pairs of GEJ and distal GC tumours in neoadjuvant chemotherapy naïve patients developed independently from different origins. Two patients who received neoadjuvant chemotherapy shared clonal origins with highly similar somatic alterations. The remaining one patient who shared a rare mutation died within 6.2 months at the N3 stage. However, the enriched pathway identified from the overall mutation spectra in distal GC and GEJ carcinoma showed the close relationship of these cancers. Thus, although these cancers may have similar characteristics, histopathological and genetic profiling from single tumour specimens may still underestimate the mutational burden and somatic heterogeneity of multiple GCs. In addition, this series of cases also showed a PD-L1 expression rate of 58.3% and 66.7% in distal GC and GEJ carcinoma, respectively, with all the cases expressing PD-1. This result suggests the potential benefit of immunotherapeutic treatments.
Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  clonality; gastric cancer; gastro-oesophageal junction carcinoma; synchronous; whole-exome sequencing

Mesh:

Substances:

Year:  2017        PMID: 28671728     DOI: 10.1002/path.4932

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  4 in total

1.  Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status.

Authors:  Lei Wang; Qiongyan Zhang; Shujuan Ni; Cong Tan; Xu Cai; Dan Huang; Weiqi Sheng
Journal:  Cancer Med       Date:  2018-04-19       Impact factor: 4.452

2.  Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrence.

Authors:  John M Findlay; Edward Dickson; Cristina Fiorani; Kevin M Bradley; Somnath Mukherjee; Richard S Gillies; Nicholas D Maynard; Mark R Middleton
Journal:  Eur Radiol       Date:  2019-07-05       Impact factor: 5.315

3.  Microbiota and metabolites alterations in proximal and distal gastric cancer patients.

Authors:  Yan Yang; Daofeng Dai; Wen Jin; Yingying Huang; Yingzi Zhang; Yiran Chen; Wankun Wang; Wu Lin; Xiangliu Chen; Jing Zhang; Haohao Wang; Haibin Zhang; Lisong Teng
Journal:  J Transl Med       Date:  2022-09-30       Impact factor: 8.440

4.  Risk factors for gastric intraepithelial neoplasia in Chinese adults: a case-control study.

Authors:  Yanqiu Yu; Cheng Fang; Chunyan Peng; Shanshan Shen; Guifang Xu; Qi Sun; Lin Li; Chuan Su; Xiaoping Zou
Journal:  Cancer Manag Res       Date:  2018-08-13       Impact factor: 3.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.